or
www.spandidos-publications.com
Home  | About  | Contact
Spandidos Logo
Advanced Search
Login  | Register


congress_banner

main_table_top_image
   Current Issue Early Online Archive Manuscript Submission About Editor and Editorial Board Sitemap
CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens

Authors:
Shigebumi Tanaka, Kana Saito, Tomokazu Ito, Kohei Tajima, Akira Mogi, Yoshinori Shitara, Takaaki Sano, Hiroyuki Kuwano

Affiliations:
Department of General Surgical Science, Gunma Graduate School of Medicine, Gunma 371-8511, Japan. tanakasi@showa.gunma-u.ac.jp

Pages:
87-92

Abstract:

Although distinguishing metastatic colorectal adenocarcinoma from primary lung adenocarcinoma is often difficult, pre- or intra-operative identification is very important, as the resection areas for each diagnosis differ substantially. CDX2, a recently cloned homeobox gene, represents a highly specific and sensitive marker of colorectal adenocarcinoma. We evaluated CDX2 expression using pre- and intra-operative biopsy specimens. The study examined 50 consecutive colorectal adenocarcinoma metastases to the lung, including 20 biopsy specimens and 66 resected specimens, and 21 primary lung adenocarcinomas. All specimens were immunohistochemically stained for CDX2, cytokeratin (CK) 7, CK20 and thyroid transcription factor (TTF)-1, and scored in a semi-quantitative manner. Mean staining score in biopsy specimens was significantly higher for CDX2 than for CK20. Sensitivities for CDX2 and CK7−/20+ in biopsy specimens were 95.0 and 65.0%, respectively. If CDX2 immunostaining had not been performed, 8 biopsy specimens (40%), and 20 resected specimens (30.3%) might have been diagnosed as equivocal cases either as primary lung cancer or metastatic colorectal cancer, using other markers. These results suggest that positive CDX2 staining represents a highly sensitive and specific marker of metastatic colorectal carcinoma in both biopsy and resected specimens, and is superior to staining for the CK7−/20+ phenotype.

Oncology Reports

July 2007
Volume 18 Number 1


Viewing options: Sign up for eToc alerts

Share this article:



main_table_bottom_image